Suppr超能文献

过去 20 年美国肾细胞癌发病率和死亡率的趋势:基于 SEER 的研究。

Trends in Renal-Cell Carcinoma Incidence and Mortality in the United States in the Last 2 Decades: A SEER-Based Study.

机构信息

Faculty of Medicine, Ain Shams University, Cairo, Egypt.

Faculty of Medicine, Ain Shams University, Cairo, Egypt; Heart and Vascular Institute, Cleveland Clinic Foundation, Cleveland, OH.

出版信息

Clin Genitourin Cancer. 2019 Feb;17(1):46-57.e5. doi: 10.1016/j.clgc.2018.10.002. Epub 2018 Oct 11.

Abstract

BACKGROUND

Renal-cell carcinoma (RCC) is one of the common malignancies in the United States. RCC incidence and mortality have been changing for many reasons. We performed a thorough investigation of incidence and mortality trends of RCC in the United States using the cell Surveillance, Epidemiology, and End Results (SEER) database.

PATIENTS AND METHODS

The 13 SEER registries were accessed for RCC cases diagnosed between 1992 and 2015. Incidence and mortality were calculated by demographic and tumor characteristics. We calculated annual percentage changes of these rates. Rates were expressed as 100,000 person-years.

RESULTS

A total of 104,584 RCC cases were reviewed, with 47,561 deaths. The overall incidence was 11.281 per 100,000 person-years. Incidence increased by 2.421% per year (95% confidence interval, 2.096, 2.747; P < .001) but later became stable since 2008. However, the incidence of clear-cell subtype continued to increase (1.449%; 95% confidence interval, 0.216, 2.697; P = .024). RCC overall mortality rates have been declining since 2001. However, mortality associated with distant RCC only started to decrease in 2012, with an annual percentage change of 18.270% (95% confidence interval, -28.775, -6.215; P = .006).

CONCLUSION

Despite an overall increase in the incidence of RCC, there has been a recent plateau in RCC incidence rates with a significant decrease in mortality.

摘要

背景

肾细胞癌(RCC)是美国常见的恶性肿瘤之一。由于多种原因,RCC 的发病率和死亡率一直在发生变化。我们使用细胞监测、流行病学和最终结果(SEER)数据库对美国 RCC 的发病率和死亡率趋势进行了全面调查。

患者和方法

访问了 1992 年至 2015 年间诊断的 13 个 SEER 登记处的 RCC 病例。根据人口统计学和肿瘤特征计算发病率和死亡率。我们计算了这些比率的年变化百分比。比率表示为每 10 万人年。

结果

共回顾了 104584 例 RCC 病例,其中 47561 例死亡。总体发病率为每 100000 人年 11.281 例。发病率每年增加 2.421%(95%置信区间,2.096,2.747;P<.001),但自 2008 年以来趋于稳定。然而,透明细胞亚型的发病率继续增加(1.449%;95%置信区间,0.216,2.697;P=.024)。自 2001 年以来,RCC 的总死亡率一直在下降。然而,只有在 2012 年,远处 RCC 相关的死亡率才开始下降,年变化百分比为 18.270%(95%置信区间,-28.775,-6.215;P=.006)。

结论

尽管 RCC 的发病率总体上有所增加,但最近 RCC 的发病率已趋于平稳,死亡率显著下降。

相似文献

1
Trends in Renal-Cell Carcinoma Incidence and Mortality in the United States in the Last 2 Decades: A SEER-Based Study.
Clin Genitourin Cancer. 2019 Feb;17(1):46-57.e5. doi: 10.1016/j.clgc.2018.10.002. Epub 2018 Oct 11.
2
Has Stage Migration in Renal Cancer Run Its Course? A SEER Database Analysis.
Clin Genitourin Cancer. 2020 Aug;18(4):e368-e373. doi: 10.1016/j.clgc.2020.01.005. Epub 2020 Jan 31.
5
Rising incidence of small renal masses: a need to reassess treatment effect.
J Natl Cancer Inst. 2006 Sep 20;98(18):1331-4. doi: 10.1093/jnci/djj362.
7
Trends in cause of death among patients with renal cell carcinoma in the United States: a SEER-based study.
BMC Public Health. 2023 Apr 26;23(1):770. doi: 10.1186/s12889-023-15647-2.
8
A Bayesian competing risk analysis of renal cancer patients based on SEER database.
Cancer Epidemiol. 2024 Oct;92:102624. doi: 10.1016/j.canep.2024.102624. Epub 2024 Aug 1.
9
International variations and trends in renal cell carcinoma incidence and mortality.
Eur Urol. 2015 Mar;67(3):519-30. doi: 10.1016/j.eururo.2014.10.002. Epub 2014 Oct 16.
10
A population-based competing-risks analysis of survival after nephrectomy for renal cell carcinoma.
Urol Oncol. 2014 Jan;32(1):46.e1-7. doi: 10.1016/j.urolonc.2013.06.010. Epub 2013 Sep 17.

引用本文的文献

1
Renal cancer survival in clear cell renal cancer compared to other types of tumor histology: A population-based cohort study.
PLoS One. 2025 Jul 31;20(7):e0329000. doi: 10.1371/journal.pone.0329000. eCollection 2025.
2
Ellagic acid suppresses the human renal carcinoma cell migration and invasion by targeting the RUNX2/MMP1 expression.
Int J Med Sci. 2025 Apr 22;22(10):2308-2317. doi: 10.7150/ijms.112117. eCollection 2025.
4
Analysis of Early Progression in Advanced Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab.
Cancer Diagn Progn. 2025 May 3;5(3):344-352. doi: 10.21873/cdp.10446. eCollection 2025 May-Jun.
5
Durability of Active Surveillance for Localized Renal Masses: 3-year Outcomes in the Michigan Urological Surgery Improvement Collaborative.
Eur Urol Open Sci. 2025 Mar 26;75:11-19. doi: 10.1016/j.euros.2025.02.005. eCollection 2025 May.
6
CENPF as a Potential Biomarker Associated with the Immune Microenvironment of Renal Cancer.
Technol Cancer Res Treat. 2025 Jan-Dec;24:15330338251330791. doi: 10.1177/15330338251330791. Epub 2025 Mar 31.
7
Percutaneous cryoablation of kidney tumors after partial nephrectomy.
Wideochir Inne Tech Maloinwazyjne. 2024 Oct 25;19(4):483-488. doi: 10.20452/wiitm.2024.17904. eCollection 2024 Dec 27.
8
Incidence and survival patterns of clear cell renal cell carcinoma from 2000 to 2017: A SEER Database Analysis.
J Cancer. 2025 Feb 3;16(5):1591-1597. doi: 10.7150/jca.105713. eCollection 2025.

本文引用的文献

1
Partial versus radical nephrectomy for T1b-2N0M0 renal tumors: A propensity score matching study based on the SEER database.
PLoS One. 2018 Feb 28;13(2):e0193530. doi: 10.1371/journal.pone.0193530. eCollection 2018.
2
Predictors of anti-VEGF drug-induced hypertension using different hypertension criteria: a secondary analysis of the COMPARZ study.
Ther Adv Med Oncol. 2018 Feb 5;10:1758834018755090. doi: 10.1177/1758834018755090. eCollection 2018.
3
Cancer statistics, 2018.
CA Cancer J Clin. 2018 Jan;68(1):7-30. doi: 10.3322/caac.21442. Epub 2018 Jan 4.
4
First-line vascular endothelial growth factor targeted therapy in renal cell carcinoma: priming the tumor microenvironment for immunotherapy.
Curr Med Res Opin. 2018 May;34(5):825-831. doi: 10.1080/03007995.2018.1423960. Epub 2018 Feb 1.
5
Regional Variation of Computed Tomographic Imaging in the United States and the Risk of Nephrectomy.
JAMA Intern Med. 2018 Feb 1;178(2):221-227. doi: 10.1001/jamainternmed.2017.7508.
6
Contrast-enhanced ultrasound of the kidney: a single-institution experience.
Ir J Med Sci. 2018 Aug;187(3):795-802. doi: 10.1007/s11845-017-1725-6. Epub 2017 Dec 7.
7
Recent advances in localized RCC: A focus on VEGF and immuno-oncology therapies.
Urol Oncol. 2018 Jan;36(1):23-30. doi: 10.1016/j.urolonc.2017.09.008. Epub 2017 Oct 16.
8
Is Ultrasound Useful for Further Evaluation of Homogeneously Hyperattenuating Renal Lesions Detected on CT?
AJR Am J Roentgenol. 2017 Sep;209(3):604-610. doi: 10.2214/AJR.17.17814. Epub 2017 Jul 5.
10
Renal Mass and Localized Renal Cancer: AUA Guideline.
J Urol. 2017 Sep;198(3):520-529. doi: 10.1016/j.juro.2017.04.100. Epub 2017 May 4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验